Zhenping Zhu

Dr. Zhenping Zhu has been President of Research & Development and Chief Scientific Officer at 3SBio Inc. since January 2017. Prior to joining 3SBio,

Dr. Zhu served as Executive Vice President of Global Biopharmaceuticals and President of Kadmon China at Kadmon Corporation.

Prior to joining Kadmon, Dr. Zhu served as Vice President and Global Head, Protein Sciences and Design, at Novartis, where he established and led research groups in Basel (Switzerland), Cambridge (U.S.), and Shanghai (China), and was responsible for the discovery, design, and selection of novel biologic medicines globally.

Prior to Novartis, Dr. Zhu worked for over 12 years at ImClone Systems as Vice President of Antibody Technology and Immunology and has successfully led research teams responsible for the discovery and early development of several FDA-approved novel antibody therapeutics for various oncology indications, including cetuximab (Erbitux®), ramucirumab (Cyramza®), necitumumab (Portrazza®), and olaratumab (Lartruvo®).

Dr. Zhu is the inventor of both ramucirumab and necitumumab and was a major contributor to cetuximab and olaratumab. From 1996 to 2006, Dr. Zhu held an adjunct professorship at the Institute of Hematology, Chinese Academy of Medical Sciences, and Peking Union Medical College. Dr. Zhu has been working in the biopharmaceutical industry for over 26 years and has published over 190 peer-reviewed scientific articles.

Dr. Zhu earned his Medical Degree from Jiangxi Medical College (Nanchang, China), passed USMLE, and is certified by U.S. ECFMG. He received his M.Sc. in pharmacology from the Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China), and his Ph.D. in immunology and pathology from Dalhousie University (Halifax, Canada).

Dr. Zhu performed his postdoctoral work in antibody/protein engineering at Genentech, Inc.